Welcome to Neumedicines Inc.

Neumedicines Inc. is exclusively engaged in research and development of both prophylactics and therapeutics based on Interleukin-12 (IL-12) (HemaMax™), for the mitigation and reversal of radiological (myeloablative) and myelosuppressive effects on the human hematopoietic system.

Learn more about Neumedicines Inc.

About HemaMax™

Contract Award (BAA-BARDA-08-08)
Neumedicines Inc. is Awarded BAA-BARDA-08-08 Contract for The Development of a Therapeutic Solution for the Hematopoietic Syndrome Resulting from Exposure to Acute Ionizing Radiation by the Biomedical Advanced Research and Development Authority (BARDA). Read more...

Research Team Update
May 2008 saw the addition of Batts Laboratories and SBH Sciences to the Neumedicines' research team. Batts Laboratories will support GLP Murine studies while SBH Sciences provides support for process and assay development.

Learn more about the Neumedicines team